FENC (Fennec Pharmaceuticals) Ending Cash Position: $40.18 Mil (As of Mar. 2026)


FENC Fennec Pharmaceuticals Inc FENC
55 GF Score
Price $10.49
GF Value $10.42
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Fennec Pharmaceuticals Ending Cash Position?

Fennec Pharmaceuticals FENC +1.75% 55 Ending Cash Position is $40.18 Mil as of Mar. 2026. GuruFocus rates FENC with a GF Score™ of 55/100 and a GF Value™ of $10.42 (Fairly Valued). The stock has 2 warning signs investors should review.

Fennec Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2026 was $40.18 Mil.

Fennec Pharmaceuticals's quarterly Ending Cash Position increased from Sep. 2025 ($21.95 Mil) to Dec. 2025 ($36.79 Mil) and increased from Dec. 2025 ($36.79 Mil) to Mar. 2026 ($40.18 Mil).

Fennec Pharmaceuticals's annual Ending Cash Position increased from Dec. 2023 ($13.27 Mil) to Dec. 2024 ($26.63 Mil) and increased from Dec. 2024 ($26.63 Mil) to Dec. 2025 ($36.79 Mil).

Fennec Pharmaceuticals Ending Cash Position Related Terms

Fennec Pharmaceuticals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Fennec Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fennec Pharmaceuticals Ending Cash Position Chart

Fennec Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.10 23.77 13.27 26.63 36.79

Fennec Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.68 18.71 21.95 36.79 40.18
FENC
55GF Score
Fennec Pharmaceuticals Inc FENC
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fennec Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Fennec Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=26.634+10.154
=36.79

Fennec Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=36.788+3.391
=40.18

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $40.18 Mil mean?
Fennec Pharmaceuticals (FENC) has a Ending Cash Position of $40.18 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Fennec Pharmaceuticals and its competitors.
Is Fennec Pharmaceuticals' Ending Cash Position too high?
Fennec Pharmaceuticals' current Ending Cash Position is $40.18 Mil. Overall, Fennec Pharmaceuticals has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fennec Pharmaceuticals' Ending Cash Position compare to VRTX and REGN?
Fennec Pharmaceuticals' Ending Cash Position of $40.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Fennec Pharmaceuticals and its competitors. Fennec Pharmaceuticals's current Ending Cash Position is $40.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fennec Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Fennec Pharmaceuticals (FENC) is currently considered Fairly Valued. The stock's GF Value™ is $10.42, compared to a current price of $10.49 — trading 0.7% above its estimated fair value. The current Ending Cash Position is $40.18 Mil. Fennec Pharmaceuticals' overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Fennec Pharmaceuticals (FENC), the current Ending Cash Position is $40.18 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fennec Pharmaceuticals (FENC) Overvalued in 2026?

Based on GuruFocus' analysis, Fennec Pharmaceuticals stock appears to be overvalued. The current stock price of $10.49 is trading 0.7% above its estimated GF Value™ of $10.42. GuruFocus considers Fennec Pharmaceuticals to be Fairly Valued.

Key valuation signals for FENC:

  • Ending Cash Position: $40.18 Mil
  • GF Value™: $10.42 vs. price of $10.49 (0.7% above fair value)
  • GF Score™: 55/100 with 2 warning signs

No single metric tells the full story. See the FENC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fennec Pharmaceuticals Business Description

Other Exchanges RV41:GermanyFRX:Canada
Address 68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
55GF Score

Get the complete analysis for FENC

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.49
Price
$10.42
GF Value